Population-Level Differences in Rectal Cancer Survival in Uninsured Patients Are Partially Explained by Differences in Treatment

Abstract

© AlphaMed Press 2017. Background. Rectal cancer (RC) is a common malignancy with a substantial mortality but good survival for patients with optimally treated nonmetastatic disease. Lack of insurance may compromise access to care and therefore compromise survival. Here, we examine RC survival by insurance type. Methods. Data from the Surveillance, Epidemiology, and End Results database were used to determine 1-to 3-year survival for patients with RC by insurance type (Medicaid, uninsured, other insurance). Results. Patients with Medicaid or no insurance presented at later stages and were less likely to receive definitive surgery. Overall 3-year survival was higher for patients with other insurance compared with Medicaid-insured (122.2% units) and uninsured (118.8% units) patients. Major differences in survival were still observed after adjustment for stage. When patients with stage II and III RC were considered, 3-year survival was higher for patients with other insurance versus those with Medicaid (116.2% units) and uninsured patients (112.2% units). However, when the analysis was limited to patients with stage II and III disease who received radiation therapy followed by definitive surgery, the difference decreased to 111.8% units and 17.3% units, respectively, for Medicaid and no insurance. Conclusion. For patients with stage II and III RC, much of the difference in survival between uninsured patients and those with insurance other than Medicaid can be explained by differences in treatment. Further efforts to determine the cause of residual differences as well as efforts to improve access to standard-of care treatment for uninsured patients may improve population level survival for RC.